2254693-15-5

2254693-15-5 structure

Name: SRX3207
Chemical Name: SRX3207
CAS Number: 2254693-15-5
Molecular Formula: C₂₉H₂₉N₇O₃S
Molecular Weight: 555.65
Catalog: Signaling Pathways PI3K/Akt/mTOR PI3K
Create Date: 2020-10-18 20:06:00
Modify Date: 2024-04-05 16:26:38
SRX3207 is an orally active and first-in-class dual Syk/PI3K inhibitor. SRX3207 possesses anti-tumor activity[1].

Name	SRX3207

Description	SRX3207 is an orally active and first-in-class dual Syk/PI3K inhibitor. SRX3207 possesses anti-tumor activity[1].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> PI3K/Akt/mTOR >> PI3K Signaling Pathways >> Protein Tyrosine Kinase/RTK >> Syk
In Vitro	SRX3207 (10 μmol/L) is able to block p-AKT at concentration[1]. SRX3207 has sufficient solubility in water (43 μmol/L)[1].
In Vivo	SRX3207 (10 mg/kg, orally) increases antitumor immune response[1]. Animal Model: LLC or B16 or B16-OVA or CT26 (1 × 105) cells were injected subcutaneously into syngeneic mice[1]. Dosage: 10 mg/kg. Administration: Orally, starting from day 10 when tumors reached 100 mm3 until tumors were harvested on day 21. Result: Blocked phosphorylation of Syk at 348 site and Y525/526 site. Blocked immunosuppressive MΦ polarization. Blocked tumor growth and increased survival effectively.
References	[1]. Shweta Joshi, et al. Macrophage Syk–PI3Kγ Inhibits Antitumor Immunity: SRX3207, a Novel Dual Syk–PI3K Inhibitory Chemotype Relieves Tumor Immunosuppression. Molecular Cancer Therapeutics. 2020.